Engineered immune cells take on virus-driven cancers in early trial

This study tests a new treatment called GP350 CAR-T cells for people with blood cancers that are linked to the Epstein-Barr virus and have not responded to standard therapy. The treatment involves collecting a patient's own immune cells, modifying them to better target the cancer, and giving them back after a short course of chemotherapy. The goal is to see if the treatment can shrink tumors and clear the virus from the blood, while monitoring for side effects.